It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Whole genome sequencing (WGS) can elucidate Mycobacterium tuberculosis (Mtb) transmission patterns but more data is needed to guide its use in high-burden settings. In a household-based TB transmissibility study in Peru, we identified a large MIRU-VNTR Mtb cluster (148 isolates) with a range of resistance phenotypes, and studied host and bacterial factors contributing to its spread. WGS was performed on 61 of the 148 isolates. We compared transmission link inference using epidemiological or genomic data and estimated the dates of emergence of the cluster and antimicrobial drug resistance (DR) acquisition events by generating a time-calibrated phylogeny. Using a set of 12,032 public Mtb genomes, we determined bacterial factors characterizing this cluster and under positive selection in other Mtb lineages. Four of the 61 isolates were distantly related and the remaining 57 isolates diverged ca. 1968 (95%HPD: 1945–1985). Isoniazid resistance arose once and rifampin resistance emerged subsequently at least three times. Emergence of other DR types occurred as recently as within the last year of sampling. We identified five cluster-defining SNPs potentially contributing to transmissibility. In conclusion, clusters (as defined by MIRU-VNTR typing) may be circulating for decades in a high-burden setting. WGS allows for an enhanced understanding of transmission, drug resistance, and bacterial fitness factors.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Boston Children’s Hospital, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
2 Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
3 Socios En Salud, Lima, Peru (GRID:grid.38142.3c)
4 Texas A&M University, College Station, USA (GRID:grid.264756.4) (ISNI:0000 0004 4687 2082)
5 Imperial College, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
6 University of South Florida, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
7 Socios En Salud, Lima, Peru (GRID:grid.170693.a)
8 Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)
9 Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Socios En Salud, Lima, Peru (GRID:grid.38142.3c)
10 SUNY Downstate Medical Center, Brooklyn, USA (GRID:grid.262863.b) (ISNI:0000 0001 0693 2202)
11 Columbia University, Mailman School of Public Health, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
12 Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Massachussetts General Hospital, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)